- Home
- CHPG vs IMUX Comparison
CHPG vs IMUX Comparison
Compare CHPG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHPG | IMUX |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.3M | 85.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CHPG | IMUX |
|---|---|---|
| Price | $10.29 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 2.9K | ★ 1.6M |
| Earning Date | 01-01-0001 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $264.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $0.51 |
| 52 Week High | $10.28 | $1.39 |
Technical Indicators
Market Signals| Indicator | CHPG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.10 |
| Support Level | N/A | $0.59 |
| Resistance Level | N/A | $0.71 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 80.36 |
Price Performance
Historical ComparisonAbout CHPG ChampionsGate Acquisition Corporation Class A Ordinary Share
Championsgate Acquisition Corp is a blank check company.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.